PH12015000305A1 - Antibacterial and antifungal berberine - pva gel patch - Google Patents
Antibacterial and antifungal berberine - pva gel patch Download PDFInfo
- Publication number
- PH12015000305A1 PH12015000305A1 PH12015000305A PH12015000305A PH12015000305A1 PH 12015000305 A1 PH12015000305 A1 PH 12015000305A1 PH 12015000305 A PH12015000305 A PH 12015000305A PH 12015000305 A PH12015000305 A PH 12015000305A PH 12015000305 A1 PH12015000305 A1 PH 12015000305A1
- Authority
- PH
- Philippines
- Prior art keywords
- berberine
- pva
- patch
- gel
- pcnt
- Prior art date
Links
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 229940093265 berberine Drugs 0.000 title claims abstract description 21
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 4
- 230000000843 anti-fungal effect Effects 0.000 title claims description 4
- 229940121375 antifungal agent Drugs 0.000 title description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 7
- 241000222122 Candida albicans Species 0.000 claims abstract description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims abstract description 4
- 241000233866 Fungi Species 0.000 claims abstract 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 33
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 33
- 241000894006 Bacteria Species 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 abstract description 14
- 208000027418 Wounds and injury Diseases 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 8
- 230000001580 bacterial effect Effects 0.000 abstract description 7
- 230000029663 wound healing Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000000813 microbial effect Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 239000013641 positive control Substances 0.000 abstract description 3
- 101100243022 Mus musculus Pcnt gene Proteins 0.000 abstract 4
- 241000192125 Firmicutes Species 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000010388 wound contraction Effects 0.000 description 3
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 150000000180 1,2-diols Chemical class 0.000 description 1
- 150000000185 1,3-diols Chemical class 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241001182426 Berberis aquifolium Species 0.000 description 1
- 244000161488 Berberis lycium Species 0.000 description 1
- 235000008130 Berberis lycium Nutrition 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 235000002823 Mahonia aquifolium Nutrition 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940124537 antidiarrhoeal agent Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000010069 protein adhesion Effects 0.000 description 1
- GUOHRXPYGSKUGT-UHFFFAOYSA-N quinolizinium Chemical compound C1=CC=CC2=CC=CC=[N+]21 GUOHRXPYGSKUGT-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 229920003170 water-soluble synthetic polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the development of berberine-PVA gel patch and assessment of its microbial inhibiting and wound healing activity. Formation of an N-O bond facilitates the bonding between berberine and PVA as confirmed by FTIR analysis. The best ratio of berberine-PVA gel patch was determined to be 4 pcnt (w/v) that exhibit inhibiting activity against gram positive bacteria Staphylococcus aureus and fungi Candida albicans. The percentage wound closure at 10 days for the different treatment groups were as follows: 92.18 pcnt for the berberine-PVA gel treated animals, 51.9 pcnt for the PVA-gel treated animals and 81.24 pcnt for the positive control. Moreover, bacterial count for berberine-PVA gel was observed to decrease greatly compared with that of the positive control. These findings suggest that berberine-PVA gel patch could be an alternate patch with wound healing activity against gram positive bacteria and fungi comparable with conventional patch available in the market.
Description
SPECIFICATION ©
ANTIBACTERIAL AND ANTIFUNGAL BERBERINE-PVA GEL PATCH - -
Technical Field oo
The present invention relates to the formation of a gel patch by - bonding berberine and polyvinyl alcohol. The final product serves as ) ’ an antibacterial and antifungal gel patch that can be used to prevent = wound infection. The present technology also includes an v1 assessment of the wound healing activity of the gel patch. -
SE
Background of the Invention: o
The use of antimicrobial agents has been utilized for several years. =
Identification of antimicrobial agent and bonding interaction in one could be a great challenge to establish a potent product in the future such as gels. pant
Today's mainstay for the treatment of wound infection is a systemic antibiotic therapy even though it is associated with an increased development of antibiotic drug resistance and adverse side effects (Jacobsen, 2011). Moreover, most systemic agents have poor tissue penetration. Thus, topical antibiotics in the form of gels, creams, ointment can be greatly use for skin wound healing as it can be applied directly to the wound site; it reduces the induction of bacterial resistance and also, prevents systematic toxicity and side effects. ’s ; Cs
Berberine :
Berberine is an isoquinoline-type alkaloid isolated from many kinds of medicinal plants such as Berberis aristata, Berberis aquifolium, and Berberis vulgaris. This compound is usually present in the roots, rhizome, and stem of the plants. It exhibits a strong yellqw color that is why it is often used as dye for wool, leather and wood. It also oY
A exhibits yellow fluorescence under ultraviolet light, thus, used in ° staining heparin in mast cells. i
Berberine has a long history of medicinal use in both Ayurvedic and ~
Chinese medicine. It is known to have antidiabetic, antidiarrhoeal, = hypotensive, anti-inflammatory and antimicrobial properties.
E "
C] + o 0 AN be
OCH;
CO] —
OCHj,4
Figure 1. Structure of Berberine.
IUPAC name eo 5,6-dihydro-9, 10-dimethoxy-benzo[g]-1.3- benzodioxolo[5,6a]quinolizinium
Molecular formula * CzHisNO,
In the study conducted by Sarkar et al., (2011), berberine chloride was placed on textile substrate and was determined to inhibit the growth of Staphylococcus aureus. The substrates used were 100% polyester, 100% nylon and 50% cotton-50% polyester blend.
Reduction of bacterial count was observed to be about 62-76%. j
Polyvinyl alcohol (PVA) :
Polyvinyl alcohol (PVA) is a water-soluble synthetic polymer commonly used in papermaking, textiles, and a variety of coatings. It is white (colorless) and odorless compound. It is sometimes supplied as beads or as solutions in water. PVA is an atactic material that exhibits crystallinity. In terms of microstructure, it is composed mainly i of 1,3-diol linkages with a few percentage of 1,2-diol depending on - the conditions of the polymerization of the vinyl ester precursor. It has - resistant to oil, grease and solvents. PVA is well known for its = processability, strength, and long-term temperature and PH stability. =
The characteristics which make it ideal for biomedical use are its . : biocompatibility, non-toxicity, and minimal cell and protein adhesion. -
Solute diffusion through PVA membranes becomes a greater function = of temperature, ionic strength, and pH of the swelling agent. The oO homopolymers can be prepared via a chemical technique where 5 glutaraldehyde and ethylene glycol dimethacrylate (EGDMA) are = used as crosslinking agents for PVA -
Polyvinyl alcohol has excellent film forming, emulsifying and adhesive properties. It has high tensile strength and flexibility as well as high oxygen and aroma barrier properties. pe 84] n
Fugure 2. Structure of Polyvinyl alcohol.
The present Invention:
PHASE I: Preparation and Characterization of Berberine-PVA gel patch
Analytical Grade of Polyvinyl alcohol was purchased at Sigma-
Aldrich. Five percent (5%) of PVA was prepared into distilled water.
The mixture is heated with ‘continuously stiring until all powder polymer are dissolved. :
Analytical grade Berberine Chloride was purchased at Sigma-
Aldrich. Different concentration 2%, 3%, 4% and 5% (wiv) were prepared into distilled water ang were heated until Berberine chloride > is fully dissolved. —
Ten (10 ml) of PVA solution was combined with 10m distilled water - and heated. About 1.59 of Agar was dissolved into heated solution 5 3 With continuously stirring. 3.5 my berberine solution was added drop n by drop with continuously stirring for the properly distribution of the i. drug and to achieve the perfect formulation ang consistency. The = solution was continuously heated until its color change from opaque o to clear. dies ll o ", Best formulation of bonded Gel was freeze dried and analyzed = using Fourier Transform Infrared Spectrometer (FT-IR) together with
PVA and Berberine alone to determine its bonding interaction. The . product was also analyzed by X-Ray Diffraction.
Preparation of berberine — PVA ee * 2% erie Fv * 3% Berberine-PVA * 4% Berberine-PVA
The formed gel shows a gel like consistency, bright yellow in color and slightly greasy that indicates that the berberine is release by the vehicle. As the concentration of Berberine increases the intensity of the color of the gel also increases and also as the miscibility of the
Berberine-PVA is change. As observed 5% berberine are already immisible with PVA and forming a suspension.
The FT-IR spectrum of pure Berberine displayed aromatics C-C stretch (in-ring) between 15685-1600 cm’ in addition of prominent peaks is aromatic amines C-N stretch between 1250-1280 cm’ and 0 ethers C-O stretch between 1000-1050 cr The spectrum of pure —
PVA displayed the —OH peak around 3415.81 cm which indicates the free ends of the polymer that can possibly bond with other 5 substances. An alkanes C-H bend peak at 2900-2950 cn and 1442 i. cm'and C-O stretch, alcohol are visible at 1093 cn. The spectrum of os the bonded gel displayed —-OH peak around 3416.45 cm. Shifting of oe peaks are observed, the appearance of amines N-H bend peak at ol 1623.95 cm’ and the formation of nitro compounds N-O at 1506.14 o cm, alkanes C-H bend peaks at 1388.22 ci and the formation of C-0 = stretch around 1042.42-1103.03 cm’ peaks. Appearance of peaks : around 1506.18 is the indication of the bonding interaction of the - two. The new peaks formed indicate the formation of the N-O bond! between berberine and PVA. - oo
Relative peak intensities of Berberine displayed at © around 25.82 and 7.62. Berberine shows a remarkable of complexity of crystal structure due to its purity, crystalline form has its own distinctive peaks in the XRD patterns. Relative Peak intensities of PVA are displayed 26 around 20.0 according to the peak this shows a remarkable complexity of polymer crystal and this pattern has its own distinctive peaks from the Berberine and the bonded gel. Relative
Peak intensities of the binded gel are displayed 20 around 20.12, 25.16, 40.28, 50.36 and 65.48. intensities around 20.12 and 25.16 are probably crystal structure of berberine and PVA based on their intensities alone while the other intensities are correspond to the new crystal structure form due to the binding interaction of the two. The increases of number of peaks intensities observe from the bonded gel are product of the formation of bonds resulted to several diffraction or formed peaks. ce . Ya . : reed Co re EEL “ ~ J : 2 ACI = EPR .
PHASE Il: Microbial Inhibiting Activity ©
The microbial inhibiting activity assay was done on Escherichia coli i
Staphylococcus aureus and Candida albicans by standard disc = diffusion method. Briefly Mueller-hinton broth/agar medium was used 5 to cultivate the bacteria. Fresh overnight of inoculum was spread on o to Mueller-Hinton agar plates. Sterile Paper disc of 5mm diameter fri (Containing 2%,3% and 4% of Bonded Gel (wiv) along with pure =
Berberine as its standard antibacterial agent ang PVA containing disc 0 were placed in each plate. Incubation followed that took 12 to 24 hrs or with its optimum temperature 37-49 °C for E. coli 37-48 °C for ©
Staphylococcus and 38-42 °C for the Candida. "
The best concentration of bonded gel is 4% Berberine-PVA gel in tye... terms of its microbial inhibiting activity. The 4% gel inhibits an fens average 40.52 mm which is susceptible to the gram (+) bacteria
Staphylococcus aureus and also inhibits an average 35.21 mm which is intermediate to fungi Candida albicans. These zones of inhibitions determined as indirect measure to activity of the Berberine-PVA bonded gel to inhibit the growth of bacteria. This also shows that the bonded gel has no effect to the gram (-) bacteria E. coli because it has no inhibition among experimental and control group.
PHASE Ill: In-Vivo assessment of Wound Healing Activity against
Staphylococcus aureus i nfected wound
Experimental rats weighing approximately 450-500 were anesthetized with diethyl ether, and their dorsal hair was clipped. Two 1.5 x 1.5-cm full-thickness wounds were created on the rats’ dorsum by sharp excision of skin. Naprex (23 mg/kg subcutaneously) was administered for analgesia. Staphylococcus aureus bacteria were ) grown in nutrient broth overnight at 37°C. Animals were infected 30 minutes later by applying Staphylococcus aureus (1 x 108 colony- forming units in 0.1 mL saline) into each dorsal wound. Bacterial concentration in the inoculum was confirmed by plating serial > dilutions on nutrient agar and counting colonies after 24 hours’ - incubation at 37°C. The initial bacteria count were determined to be - 500 CFU for each treatment group. =
The infected rats were equally divided into three treatment groups " (5 in each group): topical application of 4% Berberine-PVA gel at 3 bs hours after wound Creation and daily; water-based control gel vehicle uv 3 hours after wound creation and daily; Duoderm Extra Thin at 3 0 hours after wound creation and daily. Wound surface on days 3,7 oo and 10 after wound creation was evaluated, of cm? unit, and the o percentage of healing was normalized by the fellewina formula: y
Wound contraction (%)= Y24nd surface on day 1-wound surface on day x oe rn Leondayx 100 where x is the day when the wound surface is evaluated.
The wound was swabbed and fixed on the surface of a glass slide using a gentle flame. The heat-fixed smear of bacterial culture was stained following the Gram Stain procedure. After staining, the smear was viewed using a light microscope under oil-immersion objective in order to determine the bacterial count.
The percentage of wound contraction in berberine-polyvinyl alcohol gel medicated group was reduced by 32.8% on day 3 and 92.18% on day 10. This calculated % wound contraction for the berberine-PVA gel patch is greater than that of the negative and positive control group which were 9.16% and 21.42% on day 3 and 51.91% and 81.24% on day 10 respectively. Thus, it can be noted that the topical application of berberine-PVA gel on the experimentally excised wound surface can accelerate the wound healing process.
The bacterial count in berberine-polyviny! alcohol gel treated group was reduced to 4.6 CFU after 24 hr treatment while the reference patch, Duoderm yielded 3 bacterial count of 102 cf U. i” -
LI
Sr o
Claims (3)
1. Berberine and Polyvinyl alcohol may be bonded using the ,, ae procedure/process stated to produce a gel patch. &
2. That claim 1 was bonded due to the formation of an N-O bond 1 based on FT-IR analysis. $b. -
3. That claim 1 has antibacterial activity against gram (+) bacteria . such as Staphylococcus aureus and antifungal activity against hs fungi such as Candida albicans, po dimes © lo. SE o . oY! : / [Ee
| a. J, - ;
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PH12015000305A PH12015000305A1 (en) | 2015-09-10 | 2015-09-10 | Antibacterial and antifungal berberine - pva gel patch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PH12015000305A PH12015000305A1 (en) | 2015-09-10 | 2015-09-10 | Antibacterial and antifungal berberine - pva gel patch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015000305A1 true PH12015000305A1 (en) | 2017-03-13 |
Family
ID=58412728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015000305A PH12015000305A1 (en) | 2015-09-10 | 2015-09-10 | Antibacterial and antifungal berberine - pva gel patch |
Country Status (1)
| Country | Link |
|---|---|
| PH (1) | PH12015000305A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110755610A (en) * | 2019-09-29 | 2020-02-07 | 天津科技大学 | Antibacterial hydrogel with aggregation-induced emission characteristic and preparation method thereof |
-
2015
- 2015-09-10 PH PH12015000305A patent/PH12015000305A1/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110755610A (en) * | 2019-09-29 | 2020-02-07 | 天津科技大学 | Antibacterial hydrogel with aggregation-induced emission characteristic and preparation method thereof |
| CN110755610B (en) * | 2019-09-29 | 2022-04-08 | 天津科技大学 | Antibacterial hydrogel with aggregation-induced emission effect and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aruan et al. | Polyvinyl alcohol/soursop leaves extract composite nanofibers synthesized using electrospinning technique and their potential as antibacterial wound dressing | |
| Napavichayanun et al. | Interaction and effectiveness of antimicrobials along with healing-promoting agents in a novel biocellulose wound dressing | |
| Ebrahimi et al. | Biosynthesis of copper nanoparticles using aqueous extract of Capparis spinosa fruit and investigation of its antibacterial activity | |
| Das et al. | Biosynthesis of silver nanoparticles using bark extracts of Butea monosperma (Lam.) Taub. and study of their antimicrobial activity | |
| AU2018349776B2 (en) | Amphiphilic antimicrobial hydrogel | |
| Yahya et al. | Biofilm killing effects of Chromolaena odorata extracts against Pseudomonas aeruginosa | |
| Samling et al. | Cynometra cauliflora essential oils loaded-chitosan nanoparticles: Evaluations of their antioxidant, antimicrobial and cytotoxic activities | |
| Fang et al. | Supermolecular film crosslinked by polyoxometalate and chitosan with superior antimicrobial effect | |
| Shipovskaya et al. | Structure and properties of chitosan salt complexes with ascorbic acid diastereomers | |
| Hashemi et al. | Preparation and evaluation of polycaprolactone/chitosan/Jaft biocompatible nanofibers as a burn wound dressing | |
| Chandika et al. | Enhanced wound-healing capability with inherent antimicrobial activities of usnic acid incorporated poly (ε-caprolactone)/decellularized extracellular matrix nanofibrous scaffold | |
| Fei et al. | Biomimetic cerium oxide loaded gelatin PCL nanosystems for wound dressing on cutaneous care management of multidrug-resistant bacterial wound healing | |
| PH12015000305A1 (en) | Antibacterial and antifungal berberine - pva gel patch | |
| Abu-Huwaij et al. | Synthesis of transdermal patches loaded with greenly synthesized zinc oxide nanoparticles and their cytotoxic activity against triple negative breast cancer | |
| CN104784103B (en) | Based on oligomeric amino acid amphiphile, amphiphilic molecule injectable anti-bacterial hydrogel | |
| US9044526B2 (en) | Medical product containing active component of propolis or grapefruit seed extract and manufacturing method thereof | |
| Chao et al. | Synthesis and characterization of ionic liquid microneedle patches with different carbon chain lengths for antibacterial application | |
| Abdelazim et al. | In vitro and in vivo studies of Syzygium cumini-loaded electrospun PLGA/PMMA/collagen nanofibers for accelerating topical wound healing | |
| CN115304053B (en) | Carbon nanodot, injectable carbon nanodot-epsilon-polylysine hydrogel and preparation method and application thereof | |
| CN111100032A (en) | Preparation method and application of rare earth Schiff base complex containing ethoxy salicylaldehyde 1, 4-butanediamine | |
| GERGEROGLU et al. | Functional composite nanofibers derived from natural extract of Satureja hortensis | |
| Aboalhaija et al. | In vitro and in vivo evaluation of the wound healing potential of the extracts of Schinus molle L.(Anacardiaceae) grown in Jordan | |
| Rajkumar et al. | Green synthesis of gelatin-loaded magnesium hydroxide nanocomposite biomaterial using Coleus amboinicus leaf extract for enhanced antibacterial, antioxidant, anticholinergic, and wound healing activities | |
| Moslem et al. | Antimicrobial and cellular activity of poly (L-lactide)/chitosan/Imipenem antibiotic composite nanofibers | |
| CN114456239A (en) | Shengtai element, external antibacterial peptide gel preparation prepared from Shengtai element and application of gel preparation |